Article thumbnail

One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial

By R Pratley, M Nauck, T Bailey, E Montanya, R Cuddihy, S Filetti, A Garber, A B Thomsen, H Hartvig and M Davies
Topics: Diabetes
Publisher: Blackwell Publishing Ltd
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2008). 10-year follow-up of intensive glucose control in type 2 diabetes.
  2. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus. Clin Ther
  3. (2010). Association. Standards of medical care in diabetes–2010. Diabetes Care
  4. (2010). Available from: loads/Drugs/GuidanceComplianceRegulatoryInfor mation/Guidances/ucm071624.pdf (accessed 7
  5. (2009). diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care
  6. (2009). Differentiating incretin therapies based on structure, activity, and metabolism: focus on liraglutide. Pharmacotherapy
  7. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycaemic control, weight gain, and hypoglycaemia in type 2 diabetes.
  8. (2010). Effi-cacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet
  9. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin,
  10. (2006). Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care
  11. (2008). Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. Vasc Health Risk Manag
  12. (2003). GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics.
  13. Guidance for industry. Diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention.
  14. (2009). How does treatment satisfaction work?: Modeling determinants of treatment satisfaction and preference. Diabetes Care
  15. (2009). LEAD-4 Study Investigators. Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD). Diabetes Care
  16. (2009). Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet
  17. (2010). Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet
  18. (2009). Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus: a randomised controlled trial (LEAD-5 met+SU). Diabetologia
  19. (2009). Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med
  20. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care
  21. Once weekly taspoglutide, a human GLP-1 analog, is superior to sitagliptin in improving glycaemic control and weight loss in patients with type 2 diabetes (T2D): results from the T-emerge 4 trial. Diabetes
  22. (2009). pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue. Mol Cell Endocrinol
  23. (2010). Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia
  24. (2011). sitagliptin 1-year results ª 2011 Blackwell Publishing Ltd Int J Clin Pract,
  25. (2009). Statement by an American Association of Clinical Endocrinologists ⁄American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycaemic control. Endocr Pract
  26. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet
  27. (2002). The longacting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice.
  28. (2009). The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies. Diabetes Obes Metab
  29. (2011). Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med
  30. (2002). Writing committee for the Diabetes Control and Complications Trial ⁄ Epidemiology of Diabetes Intervention and Complications Study Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA